While cytokine release syndrome and immune effector cell‐associated neurotoxicity
syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell …

Simple Summary Cachexia occurs in up to 80% of patients with cancer. Although cancer-
associated cachexia dramatically decreases overall survival and quality of life, it is often …

The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …

Background This systematic review aimed to characterise the cognitive outcomes of patients
who received chimeric antigen receptor T-cell therapy. Methods A systematic search of the …

Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought
substantial improvement in clinical outcomes in patients with relapsed/refractory B cell …

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with
relapsed/refractory B-cell-derived hematologic malignancies. To date, six CAR T-cell …

Abstract Purpose of Review To outline the spectrum of neurotoxicity seen with approved
immunotherapies and in pivotal clinical trials including immune checkpoint inhibitors …

Abstract Objectives Chimeric Antigen Receptor (CAR) T-cell treatment is associated with
several unique toxicities, and the short-term symptom trajectory in the immediately after …

Background The short-term complications from chimeric antigen receptor T-cell therapy
(CART) are well characterized, but the long-term complications still need to be further …

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical
responses in hematologic malignancies. Recent advances in CAR T-cell therapy have …